Advertisement
ABEO vs CRBP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Buy and CRBP is a StrongBuy.
ABEO in +2.47% Uptrend, advancing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABEO advanced for three days, in 209 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABEO's RSI Indicator exited the oversold zone, 22 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where ABEO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for ABEO just turned positive on October 27, 2026. Looking at past instances where ABEO's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
ABEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABEO as a result. In 78 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 50-day moving average for ABEO moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ABEO entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.898) is normal, around the industry mean (3.104). P/E Ratio (-3.512) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (13.089) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. ABEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRBP's Stochastic Oscillator descending into oversold zone
The Stochastic Oscillator for CRBP moved into oversold territory on November 02, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CRBP just turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
Following a +6.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 228 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 50-day moving average for CRBP moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CRBP entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.732) is normal, around the industry mean (3.104). P/E Ratio (-0.633) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ABEO | CRBP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 77 | 92 | |
P/E GROWTH RATING 1..100 | 98 | 9 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABEO's Valuation (30) in the Pharmaceuticals Generic industry is somewhat better than the same rating for CRBP (63) in the Biotechnology industry. This means that ABEO’s stock grew somewhat faster than CRBP’s over the last 12 months.
ABEO's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as CRBP (100) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CRBP’s over the last 12 months.
ABEO's SMR Rating (98) in the Pharmaceuticals Generic industry is in the same range as CRBP (98) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CRBP’s over the last 12 months.
ABEO's Price Growth Rating (77) in the Pharmaceuticals Generic industry is in the same range as CRBP (92) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CRBP’s over the last 12 months.
CRBP's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for ABEO (98) in the Pharmaceuticals Generic industry. This means that CRBP’s stock grew significantly faster than ABEO’s over the last 12 months.
| ABEO | CRBP | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | N/A |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 85% | N/A |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| Advances ODDS (%) | 6 days ago 83% | 7 days ago 81% |
| Declines ODDS (%) | 2 days ago 84% | 9 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 81% | N/A |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABEO’s FA Score shows that 1 FA rating(s) are green while CRBP’s FA Score has 1 green FA rating(s).
- ABEO’s FA Score: 1 green, 4 red.
- CRBP’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABEO’s TA Score shows that 5 TA indicator(s) are bullish while CRBP’s TA Score has 3 bullish TA indicator(s).
- ABEO’s TA Score: 5 bullish, 4 bearish.
- CRBP’s TA Score: 3 bullish, 3 bearish.
Price Growth
ABEO (@Biotechnology) experienced а -1.39% price change this week, while CRBP (@Biotechnology) price change was -1.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was -12.02%, and the average quarterly price growth was -17.00%.
Reported Earning Dates
ABEO is expected to report earnings on Nov 11, 2026.
CRBP is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-2.06% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HEFA | 46.37 | 0.07 | +0.15% |
| iShares Currency Hedged MSCI EAFE ETF (HEFA) | |||
| EFZ | 23.13 | -0.10 | -0.43% |
| ProShares Short MSCI EAFE (EFZ) | |||
| ACYS | 20.32 | -0.14 | -0.68% |
| FT Vest Laddered Autocallable Barrier & Resilient Income ETF (ACYS) | |||
| VPV | 10.83 | -0.09 | -0.82% |
| Invesco Pennsylvania Value Municipal Income Trust | |||
| XXV | 21.02 | -0.37 | -1.73% |
| Simplify Ancorato Target 25 Distribution ETF (XXV) | |||